Cargando…

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II

Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieira, Raquel, Souto, Selma B., Sánchez-López, Elena, López Machado, Ana, Severino, Patricia, Jose, Sajan, Santini, Antonello, Silva, Amelia M., Fortuna, Ana, García, Maria Luisa, Souto, Eliana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780268/
https://www.ncbi.nlm.nih.gov/pubmed/31466386
http://dx.doi.org/10.3390/jcm8091332
_version_ 1783457092039868416
author Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Silva, Amelia M.
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
author_facet Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Silva, Amelia M.
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
author_sort Vieira, Raquel
collection PubMed
description Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
format Online
Article
Text
id pubmed-6780268
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67802682019-10-30 Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Silva, Amelia M. Fortuna, Ana García, Maria Luisa Souto, Eliana B. J Clin Med Review Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed. MDPI 2019-08-28 /pmc/articles/PMC6780268/ /pubmed/31466386 http://dx.doi.org/10.3390/jcm8091332 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Silva, Amelia M.
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title_full Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title_fullStr Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title_full_unstemmed Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title_short Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II
title_sort sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—strategies for in vivo administration: part-ii
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780268/
https://www.ncbi.nlm.nih.gov/pubmed/31466386
http://dx.doi.org/10.3390/jcm8091332
work_keys_str_mv AT vieiraraquel sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT soutoselmab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT sanchezlopezelena sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT lopezmachadoana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT severinopatricia sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT josesajan sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT santiniantonello sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT silvaameliam sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT fortunaana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT garciamarialuisa sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii
AT soutoelianab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromestrategiesforinvivoadministrationpartii